Lymphoma - T-cell lymphoma

The PBS subsidises brentuximab vedotin or vorinostat for patients with cutaneous T-cell lymphoma (CTCL), and brentuximab vedotin for patients with peripheral T-cell lymphoma (PTCL).

You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with brentuximab vedotin under the National Health Act 1953, section 100 for patients with CTCL and PTCL.

The PBS subsidises treatment with vorinostat under the National Health Act 1953 section 85 for patients with CTCL.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing brentuximab vedotin or vorinostat.

Section 100 arrangements

Brentuximab vedotin

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a public participating hospital.

This item isn’t PBS-subsidised for public hospital in-patients.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised brentuximab vedotin or vorinostat to treat CTCL or PTCL can be made either in:

All written applications must include the completed:

  • authority prescription form or forms
  • relevant initial authority application form
  • relevant attachments.

Select the authority application form relevant to the condition treated and the medication being prescribed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised brentuximab vedotin or vorinostat to treat CTCL or PTCL can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 26 September 2022